MDM2 as MYCN transcriptional target: implications for neuroblastoma pathogenesis.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Cancer Letters

• Publication date

  2005-10-18

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.CANLET.2005.01.050PMID 15927364
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma.

  2005cited by this paper
• Pediatric neuroblastomas: genetic and epigenetic 'danse macabre'.

  2004cited by this paper
• Radiosensitization by Antisense Anti-MDM2 Mixed-Backbone Oligonucleotide in in Vitro and in Vivo Human Cancer Models

  2004cited by this paper
• MYCN in neuronal tumours.

  2004cited by this paper
• A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans.

  2004cited by this paper
• In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

  2004cited by this paper
• Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification.

  2004cited by this paper
• MDM2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation

  2003cited by this paper
• p53-independent functions of MDM2.

  2003cited by this paper
• Cell cycle regulatory functions of the human oncoprotein MDM2.

  2003cited by this paper
• Switching mechanisms of cell death in mdm2- and mdm4-null mice by deletion of p53 downstream targets.

  2003cited by this paper
• Decision making by p53: life, death and cancer

  2003cited by this paper
• Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy

  2003cited by this paper
• Mdm2 haplo‐insufficiency profoundly inhibits Myc‐induced lymphomagenesis

  2003cited by this paper
• The requirement for evasion of programmed cell death in neuroblastomas with MYCN amplification.

  2003cited by this paper
• Myc pathways provoking cell suicide and cancer

  2003cited by this paper
• Identification of unknown target genes of human transcription factors using chromatin immunoprecipitation.

  2002cited by this paper
• Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines.

  2001cited by this paper
• Requirement for HDM2 Activity in the Rapid Degradation of p53 in Neuroblastoma*

  2001cited by this paper
• p53, Mdm2, and c‐Myc overexpression is associated with a poor prognosis in aggressive non‐Hodgkin's lymphomas

  2001cited by this paper
• MDM2 mediated nuclear exclusion of p53 attenuates etoposide-induced apoptosis in neuroblastoma cells.

  2001cited by this paper
• p53 cellular localization and function in neuroblastoma: evidence for defective G(1) arrest despite WAF1 induction in MYCN-amplified cells.

  2001cited by this paper
• Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN

  2000cited by this paper
• Absent or reduced expression of the caspase 8 gene occurs frequently in neuroblastoma, but not commonly in Ewing sarcoma or rhabdomyosarcoma.

  2000cited by this paper
• MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins.

  2000cited by this paper
• Down-regulation of endothelial cell growth inhibitors by enhanced MYCN oncogene expression in human neuroblastoma cells.

  1999cited by this paper
• Oncoprotein MDM2 overexpression is associated with poor prognosis in distinct non-Hodgkin's lymphoma entities.

  1999cited by this paper
• Transient excess of MYC activity can elicit genomic instability and tumorigenesis.

  1999cited by this paper
• Wild-type p53 can induce p21 and apoptosis in neuroblastoma cells but the DNA damage-induced G1 checkpoint function is attenuated.

  1999cited by this paper
• MYC oncogenes and human neoplastic disease

  1999cited by this paper
• Loss of one but not two mdm2 null alleles alters the tumour spectrum in p53 null mice

  1999cited by this paper
• MycN and IFNgamma cooperate in apoptosis of human neuroblastoma cells.

  1998cited by this paper
• MycN and IFNγ cooperate in apoptosis of human neuroblastoma cells

  1998cited by this paper
• Nucleo‐cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein

  1998cited by this paper
• Nuclear Export Is Required for Degradation of Endogenous p53 by MDM2 and Human Papillomavirus E6

  1998cited by this paper
• The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53.

  1998cited by this paper
• Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization.

  1998cited by this paper
• Anti-apoptosis gene, survivin, and prognosis of neuroblastoma.

  1998cited by this paper
• High prognostic significance of Mdm2/p53 co-overexpression in soft tissue sarcomas of the extremities

  1998cited by this paper
• Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53.

  1997cited by this paper
• Targeted expression of MYCN causes neuroblastoma in transgenic mice

  1997cited by this paper
• Mdm2 promotes the rapid degradation of p53

  1997cited by this paper
• Regulation of p53 stability by Mdm2

  1997cited by this paper
• Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame

  1997cited by this paper
• Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53

  1997cited by this paper
• Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF.

  1997cited by this paper
• Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells.

  1996cited by this paper
• The p53 signal transduction pathway is intact in human neuroblastoma despite cytoplasmic localization.

  1996cited by this paper
• Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein

  1995cited by this paper
• Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53

  1995cited by this paper
• Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53

  1995cited by this paper
• Interaction between the retinoblastoma protein and the oncoprotein MDM2

  1995cited by this paper
• Elevated levels of MDM-2 and p53 expression are associated with high grade non-Hodgkin's lymphomas.

  1994cited by this paper
• Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas.

  1994cited by this paper
• Low frequency of the p53 gene mutations in neuroblastoma

  1994cited by this paper
• Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification.

  1993cited by this paper
• Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations.

  1993cited by this paper
• Mutations of the p53 gene are involved in Ewing's sarcomas but not in neuroblastomas.

  1993cited by this paper
• The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth

  1993cited by this paper
• Absence of p53 gene mutations in primary neuroblastomas.

  1993cited by this paper
• p53 Mutation and MDM2 amplification in human soft tissue sarcomas.

  1993cited by this paper
• The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.

  1992cited by this paper
• Bcl-2 initiates a new category of oncogenes: regulators of cell death.

  1992cited by this paper
• Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line.

  1991cited by this paper
• Augmented MYCN expression advances the malignant phenotype of human neuroblastoma cells: evidence for induction of autocrine growth factor activity.

  1990cited by this paper
• The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice

  1985cited by this paper

• Switching off CK2-mediated activation of survivin offers new therapeutic opportunities in neuroblastoma

  2026cites this paper
• CCNB1IP1 prevents ubiquitination‐mediated destabilization of MYCN and potentiates tumourigenesis of MYCN‐amplificated neuroblastoma

  2023cites this paper
• Targeting the Complex Protein Network of MYCN-amplified Anaplastic Ependymoma: A Case Report

  2022cites this paper
• MYCN Impact on High-Risk Neuroblastoma: From Diagnosis and Prognosis to Targeted Treatment

  2022cites this paper
• TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma

  2022cites this paper
• Integrated Genomic Profiling and Drug Screening of Patient-Derived Cultures Identifies Individualized Copy Number-Dependent Susceptibilities Involving PI3K Pathway and 17q Genes in Neuroblastoma

  2021cites this paper
• Role of Genetic and Epigenetic Alterations in Pathogenesis of Neuroblastoma

  2019cites this paper
• Comprehensive characterization of RB1 mutant and MYCN amplified retinoblastoma cell lines

  2019cites this paper
• Neuroblastoma

  2018cites this paper
• MiR-137 expression in neuroblastoma: a role in clinical course and outcome.

  2016cites this paper
• Nerve growth factor receptor negates the tumor suppressor p53 as a feedback regulator

  2016cites this paper
• Regulation of Nuclear Hormone Receptors by MYCN-Driven miRNAs Impacts Neural Differentiation and Survival in Neuroblastoma Patients.

  2016cites this paper
• Exploring Chromatin-bound MDM2 Functions in Compromised Transcriptional Regulation of p53 Target Genes

  2015cites this paper
• Prognostic significance of MDM2 gene expression in childhood neuroblastoma.

  2015influential citation
• Clinical Characteristics and Outcome of Patients with Neuroblastoma Presenting Genomic Amplification of Loci Other than MYCN

  2014cites this paper
• Splice variants of MDM2 in oncogenesis.

  2014cites this paper
• Focal DNA Copy Number Changes in Neuroblastoma Target MYCN Regulated Genes

  2013cites this paper
• Novel anthranilamide-pyrazolo[1,5-a]pyrimidine conjugates modulate the expression of p53-MYCN associated micro RNAs in neuroblastoma cells and cause cell cycle arrest and apoptosis.

  2013cites this paper
• The MYCN Oncogene

  2013cites this paper
• Neuroblastoma: Role of MDM2 and SNP309 as Markers

  2013cites this paper
• MDM2, MDMX and p53 in oncogenesis and cancer therapy

  2013cites this paper
• Neuroblastoma: Role of MYCN/Bmi1 Pathway in Neuroblastoma

  2012cites this paper
• Nódulos subcutáneos azulados en un lactante. Diagnóstico y comentario

  2012cites this paper
• Exploitation of chick embryo environments to reprogram MYCN-amplified neuroblastoma cells to a benign phenotype, lacking detectable MYCN expression

  2012cites this paper
• miRNA Expression Profiling of the Murine TH-MYCN Neuroblastoma Model Reveals Similarities with Human Tumors and Identifies Novel Candidate MiRNAs

  2011cites this paper
• Phospho-proteomic Analysis of Neuroblastoma Tumor Initiating Cell Signaling Pathways: Identification of Src Family and B Cell Receptor Signaling as Novel Drug Targets

  2011cites this paper
• MYCN oncoprotein targets and their therapeutic potential.

  2010cites this paper
• Targeting the MDM2–p53 interaction as a therapeutic strategy for the treatment of cancer

  2010cites this paper
• Myc proteins as therapeutic targets

  2010influential citation
• MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells.

  2007cites this paper
• MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death

  2006cites this paper
• MDM 2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death

  2006cites this paper